Contract Manufacturing, Finished Drug Product

Final Product Inspection: Making the Most of Your Processes

December 01, 2023

Final product inspection results should be included as part of the batch release documentation, says Susan J. Schniepp, distinguished fellow at Nelson Laboratories, LLC.

Identifying Outsourcing Marketing Trends

May 16, 2023

Outsourcing collaborations provide insight into the key drivers of market growth.

Deciding Where to Outsource in Biopharma Development and Manufacturing

August 02, 2022

Experts divulge where the industry is outsourcing most frequently, when companies should outsource more, and when performing tasks in-house might be best.

Quotient Sciences Acquires CDMO Arcinova

February 17, 2021

The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.

GRAM Partners with Johnson & Johnson for Fill/Finish of Vaccine Candidate

September 28, 2020

GRAM is expanding fill/finish capacity and is working with Janssen on tech transfer in preparation for production of Janssen’s SARS-CoV-2 vaccine candidate at GRAM’s Grand Rapids, MI facility.

Catalent Invests Millions to Create European Clinical Manufacturing Center of Excellence

July 21, 2020

Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.

Vetter Expands Fill/Finish Capacity with Acquisition of New Site in Austria

July 08, 2020

The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.

Contractors Balance Increased Demand During COVID-19

July 01, 2020

The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.

Vibalogics Manufactures Clinical Trial Material for Janssen COVID-19 Vaccine Candidate

May 18, 2020

Vibalogics is contracted to manufacture Janssen's COVID-19 candidate vaccine at its GMP-accredited facility in Cuxhaven, Germany.

Fujifilm Diosynth Biotechnologies Reserves Capacity for COVID-19 Therapeutics Accelerator

May 04, 2020

Fujifilm allocates production volumes for COVID-19 treatments in 2021 at its Denmark facility.